Post-COVID-19 neurocandidiasis

Neurol Sci. 2021 Nov;42(11):4419-4420. doi: 10.1007/s10072-021-05515-5. Epub 2021 Aug 9.

Abstract

Associated with a significant morbidity and mortality, neurocandidiasis affects severely immunocompromised patients, especially if recently treated with antibiotics or corticosteroids. We present the case of a 70-year-old man admitted to an intensive care unit due to a Sars-Cov-2 pneumonia, with fever, coma, and multifocal neurological deficits reported 13 days after extubation. After isolation of Candida albicans in both urine and blood cultures and a brain MRI with multiple gadolinium-enhanced ring lesions, a diagnosis of neurocandidiasis was assumed and aggressive antifungal therapy started. During treatment, the patient developed a hospital-acquired pneumonia with fatal outcome.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anti-Bacterial Agents / therapeutic use
  • COVID-19*
  • Humans
  • Immunocompromised Host
  • Intensive Care Units
  • Male
  • SARS-CoV-2

Substances

  • Anti-Bacterial Agents